Further elucidation of the regulatory mechanism of steatosis by IκBζ may represent a novel and attractive therapeutic target for NAFLD, diabetes, and obesity. This evidence concerns the gene NFKBIZ and metabolic dysfunction-associated steatotic liver disease.